全球血管舒縮症狀 (VMS) 市場規模、佔有率和成長分析：按治療類型、分銷管道和地區分類 - 產業預測，2024-2031 年

2022年全球血管運動症狀（VMS）市場規模估值為35億美元，預測期內（2024-2031年）複合年成長率為6.90%，從2023年的37.4億美元到2031年預計將達到63.8億美元。

血管舒縮症狀 (VMS)，如潮熱、盜汗和貧血，在月經期間很常見，通常會導致突然出汗和臉部發紅。這些症狀在停經後婦女中的頻率和強度差異很大，並且通常在停經後的頭兩年內最具挑戰性。這些症狀可能嚴重到足以干擾日常生活，對於某些女性來說可能無限期地持續存在，凸顯了月經的多樣性和個體性。多方面的神經系統症狀凸顯了全面支持的必要性，以幫助女性應對這段時期遇到的獨特挑戰。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價值鏈分析
• 價格分析
• Start-Ups分析
• 監管環境
• 專利分析
• 管道分析
• 關鍵成功因素
• 市場吸引力指數
• 競爭程度
• 主要投資機會
• 生態系繪圖

血管舒縮症狀 (VMS) 市場：依治療類型

• 市場概況
• 荷爾蒙
• 非荷爾蒙的

血管舒縮症狀 (VMS) 市場：按分銷管道

• 市場概況
• 醫院藥房
• 零售藥房
• 網路商店
• 其他

按地區分類的血管舒縮症狀 (VMS) 市場規模

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Astellas Pharma Inc.（Japan）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Sanofi SA（France）
• Eli Lilly and Company（United States）
• Novo Nordisk A/S（Denmark）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Amgen Inc.（United States）
• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan NV（United States）
• Allergan plc（Ireland）
• Endo International plc（Ireland）
• Sun Pharmaceutical Industries Ltd.（India）

Vasomotor Symptoms Market was valued at USD 3.5 billion in 2022 and is expected to rise from USD 3.74 billion in 2023 to reach a value of USD 6.38 billion by 2031, at a CAGR of 6.90% during the forecast period (2024-2031).

Vasomotor symptoms, such as hot flashes, night sweats, and anaemia, are commonly experienced during menstruation, often causing sudden sweating and facial redness. These symptoms vary greatly in frequency and intensity among postmenopausal women, with the initial two years post-menopause typically being the most challenging. The severity of these symptoms can be incapacitating, and for certain women, they may persist indefinitely, underscoring the diverse and personal nature of the menstrual journey. The multifaceted neurological symptoms emphasize the necessity for comprehensive support to address the unique challenges women encounter during this phase of life.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segmental Analysis

The vasomotor symptoms market is segmented into therapy type, distribution channel, and region. Based on therapy type, the market is segmented into Hormonal (Estrogen, Progesterone, Combination, Others), Non-Hormonal (Anti-Depressants, Others). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online stores and others. Based on region, the market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America.

Drivers of the Vasomotor Symptoms Market

Research and development (R&D) initiatives and clinical trials are pivotal in advancing our comprehension of the fundamental causes of neurological symptoms, encompassing mutations and physiological processes. This deeper insight holds the potential to facilitate the development of more precise and efficient therapies. By delving deeper into the complexities of neurological disorders through clinical trials, researchers can contribute significantly to the market's robust compound annual growth rate (CAGR). These trials not only broaden the spectrum of available treatment modalities but also stimulate market expansion by introducing novel therapeutic approaches.

Restraints in the Vasomotor Symptoms Market

The expansion of the market is constrained by the substantial expenses linked with diverse treatment approaches. Numerous stakeholders dedicate considerable resources to advancing treatment methodologies, aiming to improve recovery processes, which inevitably drives up overall expenses. These investments encompass research, development, and manufacturing, all contributing to the escalated costs of various treatment modalities. Despite the potential benefits in enhancing patient outcomes and treatment effectiveness, the heightened financial burdens pose a significant hurdle to the market's growth trajectory.

Market Trends of the Vasomotor Symptoms Market

The introduction of new interventions or the development of innovative treatments has the potential to raise awareness about vasomotor symptoms (VMS) and underscore the significance of effective treatment options. This heightened awareness can prompt more women to actively seek relief for their symptoms, thereby expanding the market for VMS treatments. Companies specializing in launching new products or treatments for VMS can potentially gain a competitive edge in this market. This advantage is particularly crucial for establishing their product as the preferred choice among healthcare providers and patients alike, solidifying its position in the treatment landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Pricing Analysis
• Start Up Analysis
• Regulatory Landscape
• Patent Analysis
• Pipeline Analysis
• Key Success Factors
• Market Attractiveness Index
• Degree of Competition
• Top Investment Pockets
• Ecosystem Mapping

Vasomotor Symptoms Market by Therapy Type

• Market Overview
• Hormonal
• Non-Hormonal

Vasomotor Symptoms Market by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Vasomotor Symptoms Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments